NasdaqGS - Delayed Quote USD
AnaptysBio, Inc. (ANAB)
21.27
-2.25
(-9.57%)
At close: 4:00:01 PM EDT
21.24
-0.03
(-0.14%)
After hours: 7:20:11 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 8 |
| Avg. Estimate | -1.57 | -1.56 | -5.68 | -4.89 |
| Low Estimate | -1.81 | -1.86 | -7.02 | -6.9 |
| High Estimate | -0.98 | -0.94 | -4.04 | -1.3 |
| Year Ago EPS | -1.71 | -1.14 | -5.12 | -5.68 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 11 | 11 | 11 | 11 |
| Avg. Estimate | 11.55M | 12.71M | 79.46M | 90.68M |
| Low Estimate | -- | -- | 27.77M | -- |
| High Estimate | 23.9M | 31.55M | 216.9M | 206M |
| Year Ago Sales | 10.97M | 30.02M | 91.28M | 79.46M |
| Sales Growth (year/est) | 5.30% | -57.64% | -12.95% | 14.11% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -0.93 | -1.61 | -1.7 | -1.46 |
| EPS Actual | -1.71 | -1.14 | -0.72 | -1.28 |
| Difference | -0.78 | 0.47 | 0.98 | 0.18 |
| Surprise % | -83.48% | 29.29% | 57.77% | 12.53% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -1.57 | -1.56 | -5.68 | -4.89 |
| 7 Days Ago | -1.57 | -1.56 | -5.68 | -4.89 |
| 30 Days Ago | -1.39 | -1.39 | -5.3 | -5.39 |
| 60 Days Ago | -1.39 | -1.39 | -5.3 | -5.39 |
| 90 Days Ago | -1.39 | -1.39 | -5.62 | -5.73 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | 1 |
| Up Last 30 Days | 3 | 3 | 4 | 4 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 3 | 4 | 2 | 3 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| ANAB | 8.35% | -37.08% | -10.90% | 13.83% |
| S&P 500 | 13.08% | 2.49% | 7.56% | 13.97% |
Upgrades & Downgrades
| Upgrade | HC Wainwright & Co.: Neutral to Buy | 6/4/2025 |
| Maintains | Guggenheim: Buy to Buy | 5/28/2025 |
| Maintains | Guggenheim: Buy to Buy | 5/6/2025 |
| Reiterates | Wedbush: Outperform to Outperform | 5/1/2025 |
| Maintains | JP Morgan: Overweight to Overweight | 3/5/2025 |
| Reiterates | HC Wainwright & Co.: Neutral to Neutral | 3/4/2025 |
Related Tickers
TRVI Trevi Therapeutics, Inc.
6.58
+10.59%
BCAX Bicara Therapeutics Inc.
11.16
+1.36%
KURA Kura Oncology, Inc.
6.45
+0.47%
COGT Cogent Biosciences, Inc.
5.64
-2.59%
PTGX Protagonist Therapeutics, Inc.
51.53
+0.92%
TSHA Taysha Gene Therapies, Inc.
2.7900
+0.36%
ORIC ORIC Pharmaceuticals, Inc.
9.08
+8.10%
KROS Keros Therapeutics, Inc.
14.82
-0.87%
KALV KalVista Pharmaceuticals, Inc.
13.54
+1.42%
QURE uniQure N.V.
14.96
-1.32%